Kura Oncology — backed Caspian advances KO — 7246 toward Phase 1 diabetes proof — of — concept study
Kura Oncology outlined a development plan for KO-7246, an oral menin inhibitor for diabetes, with an investor webcast scheduled for today. Preclinical findings were already presented at the EASD meeting, supporting a move toward clinical proof of concept. Animal studies showed improved glucose control with signs of res